生物标志物在转移性肾细胞癌对新型免疫治疗药物的反应中是否起预测作用？ - Suppr

Suppr

超能文献

Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?

作者信息

Raimondi Alessandra, Sepe Pierangela, Claps Melanie, Verzoni Elena, Procopio Giuseppe

机构信息

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy.

出版信息

Expert Opin Biol Ther. 2019 Nov;19(11):1107-1110. doi: 10.1080/14712598.2019.1651288. Epub 2019 Aug 6.

DOI:10.1080/14712598.2019.1651288

PMID:31369337

Abstract

摘要

相似文献

Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?生物标志物在转移性肾细胞癌对新型免疫治疗药物的反应中是否起预测作用？

Expert Opin Biol Ther. 2019 Nov;19(11):1107-1110. doi: 10.1080/14712598.2019.1651288. Epub 2019 Aug 6.

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.免疫治疗在尿路上皮癌和肾细胞癌中的生物标志物：PD-L1、肿瘤突变负担及其他。

J Immunother Cancer. 2018 Jan 25;6(1):4. doi: 10.1186/s40425-018-0314-1.

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma.针对肾细胞癌的 PD-1/PD-L1 通路。

Int J Mol Sci. 2019 Apr 4;20(7):1692. doi: 10.3390/ijms20071692.

Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?非小细胞肺癌中PD-1/PD-L1阻断疗法的生物标志物：PD-L1表达是患者选择的良好标志物吗？

Clin Lung Cancer. 2016 Sep;17(5):350-361. doi: 10.1016/j.cllc.2016.03.011. Epub 2016 Apr 6.

Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.原发性和转移性阴茎鳞状细胞癌中频繁的程序性死亡受体配体1（PD-L1）表达：免疫治疗方法的潜在机遇

Ann Oncol. 2016 Sep;27(9):1706-12. doi: 10.1093/annonc/mdw216. Epub 2016 May 23.

Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.肿瘤微环境免疫类型的基因组分析在 14 种实体瘤中的应用：免疫治疗意义。

Theranostics. 2017 Aug 22;7(14):3585-3594. doi: 10.7150/thno.21471. eCollection 2017.

The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.转移性透明细胞肾细胞癌患者中PD-L1表达与血管内皮生长因子靶向治疗临床结局的相关性

Oncologist. 2015 Nov;20(11):1253-60. doi: 10.1634/theoncologist.2015-0151. Epub 2015 Sep 30.

Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma.超越PD-L1阳性肿瘤细胞百分比：原发性和转移性头颈部鳞状细胞癌中诱导性与组成性PD-L1表达

Head Neck Pathol. 2018 Jun;12(2):221-229. doi: 10.1007/s12105-017-0857-3. Epub 2017 Sep 25.

Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidence.转移性 2 型乳头状肾细胞癌患者对纳武利尤单抗的显著且持久的应答：适应证内但无证据支持。

Invest New Drugs. 2017 Oct;35(5):665-668. doi: 10.1007/s10637-017-0469-5. Epub 2017 May 2.

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.在肾透明细胞癌原发灶与转移灶中 PD-L1 的差异表达。

Cancer Immunol Res. 2015 Oct;3(10):1158-64. doi: 10.1158/2326-6066.CIR-15-0043. Epub 2015 May 26.

引用本文的文献

Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma.肾细胞癌的免疫治疗靶点与疗法

Immunotargets Ther. 2020 Nov 13;9:273-288. doi: 10.2147/ITT.S240889. eCollection 2020.

Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma.晚期肾细胞癌患者的流行病学、风险评估和生物标志物。

Urol Clin North Am. 2020 Aug;47(3):293-303. doi: 10.1016/j.ucl.2020.04.002. Epub 2020 Jun 10.

The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.转移性肾细胞癌免疫治疗反应评估：临床实践中的开放性挑战。

Int J Mol Sci. 2019 Aug 30;20(17):4263. doi: 10.3390/ijms20174263.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验